spec sheet7 rows
Ipidacrine is a genuine Cold War-era Soviet original, synthesized at the National Research Center for Biologically Active Compounds in Russia and pushed through the 1970s and 1980s under the code name NIK-247, decades before it ever appeared on a Western researcher's radar. Rather than working through the single acetylcholinesterase-inhibition mechanism most of its Western contemporaries relied on, it combines that AChE blockade with direct potassium-channel blockade at nerve and muscle membranes, a dual action that boosts both central cholinergic tone and peripheral nerve-impulse conduction. It remains sold and prescribed today in Russia and several post-Soviet states as Neuromidin (also called Amiridin or, in a topical form, Axamon), for memory disorders and peripheral nerve conditions, but it never went through Western-style FDA or EMA trials and stayed essentially invisible outside that regulatory sphere, a working drug that the rest of the world simply never met.
- A genuine Soviet original still prescribed as Neuromidin
- Dual action; blocks acetylcholinesterase and potassium channels
- Lifts central cholinergic tone and peripheral nerve conduction
- Reversed scopolamine amnesia in rat water maze studies
- Rodent memory data looks striking; Western trials never happened
- Prescribed for decades across Russia and post Soviet states
- typical cholinergic side effects (GI upset, salivation) reported with clinical use in its home markets
- Ipidacrine has been in continuous clinical use in Russia since the Soviet era under the code name NIK-247, roughly the same age as several famous Western Alzheimer's drug candidates that failed, yet it remains almost completely unknown outside its home region.
Mechanism
Dual-action agent: reversibly inhibits (IC50 around 270 nM) to raise levels, while also blocking potassium channels on neuronal and muscle cell membranes to enhance nerve-impulse conduction and neuromuscular transmission.
Dosingtypical ranges, not medical advice
interested in protocols and clinical dosages? make an account to see them! ^_^
Safetyrisks and cautions, not medical advice
Epilepsy, bronchial asthma, angina, severe bradycardia, mechanical bowel or urinary obstruction and an active ulcer are hard contraindications on the Neuromidin label rather than cautions; it lowers the seizure threshold and can provoke bronchospasm. Cholinergic effects at ordinary doses are the norm: salivation, nausea, diarrhoea, sweating, muscle twitching, a slowed heart rate. Beta blockers compound the bradycardia, other cholinesterase inhibitors the rest, and anticholinergics cancel it. Tell an anaesthetist, since it antagonises non-depolarising muscle relaxants and potentiates depolarising ones. Overdose brings a cholinergic crisis.
History
Synthesized in the Soviet Union at the National Research Center for Biologically Active Compounds under the code NIK-247, with development running through the 1970s-1990s; it was never submitted for Western regulatory approval but has been marketed and prescribed in Russia and other post-Soviet countries since as Neuromidin (Amiridin, Axamon) for memory disorders and neuromuscular conditions.
Subjective profileweighing the evidence above
A real, still-used drug behind a wall of regulatory and geographic obscurity, not a failed compound so much as one that never crossed into Western medicine.
Where to buy
Suppliers
Vendors carrying Ipidacrine, with live product details and codes. Links are affiliate links that support the wiki at no cost to you.
RUPharma🌐
Ipidacrine
Research
- 1.Ipidacrine (NIK-247), a novel antidementia, rapidly enters the brain and improves scopolamine-induced amnesia in rats during the Morris water maze task
- 2.Ameliorative effects of the centrally active cholinesterase inhibitor, NIK-247, on impairment of working memory in rats
2 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
Is ipidacrine available in the United States or Europe?
No, it has never been submitted for FDA or EMA approval and is not sold in Western markets; it remains prescribed in Russia and several post-Soviet countries under names like Neuromidin, Amiridin, and Axamon.
What makes ipidacrine different from other acetylcholinesterase inhibitors?
Beyond blocking acetylcholinesterase, it also blocks potassium channels on nerve and muscle membranes, a dual mechanism that supports both its cognitive use and its separate use for peripheral nerve and neuromuscular conditions.
Limitations of the evidence
- limited independently published Western safety data given it never went through FDA/EMA trial pathways
Adverse effects
- typical cholinergic side effects (GI upset, salivation) reported with clinical use in its home markets